Ticker Details
Axon Holdings S.A. Axovant Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of dementia.
IPO Date:	June 11, 2015
Sector:	Industrials
Industry:	Aerospace and Defense
Market Cap:	$28.25B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$3.36 | 2.40%
Avg Daily Range (30 D):	$12.18 | 2.58%
Avg Daily Range (90 D):	$11.36 | 2.24%

Institutional Daily Volume
Avg Daily Volume:	.62M
Avg Daily Volume (30 D):	.87M
Avg Daily Volume (90 D):	.81M

Trade Size
Avg Trade Size (Sh.):	64
Avg Trade Size (Sh.) (30 D):	21
Avg Trade Size (Sh.) (90 D):	21

Institutional Trades
Total Institutional Trades:	3,592
Avg Institutional Trade:	$16.81M
Avg Institutional Trade (30 D):	$30.08M
Avg Institutional Trade (90 D):	$33.03M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$29.61M
Avg Closing Trade (30 D):	$61.73M
Avg Closing Trade (90 D):	$62.26M
Avg Closing Volume:	87.7K

News

Apr 8, 2026 @ 6:31 PM Why Axon Stock Bounced Back After Falling 10% Yest... Source: Jeremy Bowman

Mar 22, 2026 @ 7:15 AM 2 Tech Stocks That Could Help Make You a Fortune Source: John Ballard

Mar 19, 2026 @ 7:00 PM Carahsoft and Partners Showcase Security Solutions... Source: Not Specified

Mar 15, 2026 @ 3:00 PM Centene, Paramount Skydance, And Ulta Beauty Are A... Source: Nabaparna Bhattacharya

Mar 12, 2026 @ 2:30 AM 1 Millionaire-Maker Artificial Intelligence (AI) S... Source: Jeremy Bowman

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$1.6	$.03	$1.6
Diluted EPS	$1.51	$.03	$1.51
Revenue	$2.78B	$796.72M	$2.78B
Gross Profit	$1.66B	$461.3M	$1.66B
Net Income / Loss	$124.66M	$2.75M	$124.66M
Operating Income / Loss	$-62.08M	$-50.12M	$-62.08M
Cost of Revenue	$1.12B	$335.43M	$1.12B
Net Cash Flow	$746.63M	$-222.75M	$746.63M
PE Ratio	229.50

Splits
Sep 28, 2007	1:600
Nov 30, 2004	2:1
Apr 30, 2004	2:1
Feb 11, 2004	3:1